124 related articles for article (PubMed ID: 16373705)
1. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Summy JM; Trevino JG; Lesslie DP; Baker CH; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keats JA; Sawyer TK; Gallick GE
Mol Cancer Ther; 2005 Dec; 4(12):1900-11. PubMed ID: 16373705
[TBL] [Abstract][Full Text] [Related]
2. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.
Summy JM; Trevino JG; Baker CH; Gallick GE
Pancreas; 2005 Oct; 31(3):263-74. PubMed ID: 16163059
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
[TBL] [Abstract][Full Text] [Related]
4. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.
Trevino JG; Summy JM; Gray MJ; Nilsson MB; Lesslie DP; Baker CH; Gallick GE
Cancer Res; 2005 Aug; 65(16):7214-22. PubMed ID: 16103072
[TBL] [Abstract][Full Text] [Related]
5. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
6. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Laird AD; Li G; Moss KG; Blake RA; Broome MA; Cherrington JM; Mendel DB
Mol Cancer Ther; 2003 May; 2(5):461-9. PubMed ID: 12748308
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Han LY; Landen CN; Trevino JG; Halder J; Lin YG; Kamat AA; Kim TJ; Merritt WM; Coleman RL; Gershenson DM; Shakespeare WC; Wang Y; Sundaramoorth R; Metcalf CA; Dalgarno DC; Sawyer TK; Gallick GE; Sood AK
Cancer Res; 2006 Sep; 66(17):8633-9. PubMed ID: 16951177
[TBL] [Abstract][Full Text] [Related]
8. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration.
Ali N; Yoshizumi M; Fujita Y; Izawa Y; Kanematsu Y; Ishizawa K; Tsuchiya K; Yano S; Sone S; Tamaki T
J Pharmacol Sci; 2005 Jun; 98(2):130-41. PubMed ID: 15937404
[TBL] [Abstract][Full Text] [Related]
9. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
10. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Zheng R; Yano S; Matsumori Y; Nakataki E; Muguruma H; Yoshizumi M; Sone S
Clin Exp Metastasis; 2005; 22(3):195-204. PubMed ID: 16158247
[TBL] [Abstract][Full Text] [Related]
11. Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo.
Ischenko I; Seeliger H; Camaj P; Kleespies A; Guba M; Eichhorn ME; Jauch KW; Bruns CJ
Curr Cancer Drug Targets; 2010 Aug; 10(5):546-53. PubMed ID: 20370688
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
13. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells.
Furuno A; Watari K; Nakamura M; Fukunaga Y; Jung JH; Ono M
Int J Oncol; 2011 Feb; 38(2):493-501. PubMed ID: 21132269
[TBL] [Abstract][Full Text] [Related]
14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
[TBL] [Abstract][Full Text] [Related]
17. Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization.
Werdich XQ; Penn JS
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5047-56. PubMed ID: 17065526
[TBL] [Abstract][Full Text] [Related]
18. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
Missbach M; Jeschke M; Feyen J; Müller K; Glatt M; Green J; Susa M
Bone; 1999 May; 24(5):437-49. PubMed ID: 10321903
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
20. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Herynk MH; Zhang J; Parikh NU; Gallick GE
J Exp Ther Oncol; 2007; 6(3):205-17. PubMed ID: 17552361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
